20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy
20/20 BioLabs (AIDX) will host an investor webinar on November 4, 2026, covering OneTest commercial expansion and growth plans.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
20/20 BioLabs (AIDX) will host an investor webinar on November 4, 2026, covering OneTest commercial expansion and growth plans. The session begins at 12:00 p.m. Eastern time, with CEO Jonathan Cohen discussing the proposed laboratory franchise model, 2027 licensing plans, potential acquisitions, FDA planning and firefighter cancer screening initiatives.
The agenda also includes the company's goal of achieving Medicare reimbursement for multi-cancer early detection testing by the end of 2028. A live question-and-answer session is planned, and a replay will be available through the investor relations website. The webinar will not cover third-quarter 2026 financial results.
Details
Market move: AIDX -6.94% vs previous close. November investor webinar
On Oct 29, the day this news came out, the latest delayed price for AIDX is 6.94% below the previous close. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $0.23.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Terms
mced medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CEO Jonathan Cohen to Discuss Laboratory Franchise Model, 2027 Licensing Plans, Potential Acquisitions, FDA Strategy, and Firefighter Cancer Screening Initiatives
Webinar to Be Held Wednesday, November 4, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open
GAITHERSBURG, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, November 4, 2026, at 12:00 p.m. Eastern time.
Jonathan Cohen, President and Chief Executive Officer of 20/20 BioLabs, will discuss the Company's plans to expand the commercial reach of OneTest™ through its laboratory franchise and licensing strategies, as well as potential acquisitions, U.S. Food and Drug Administration (“FDA”) planning, and new Maryland legislation expected to expand state-funded firefighter cancer screening.
To access the webinar, please use the following information:
| Date: | Wednesday, November 4, 2026 |
| Time: | 12:00 p.m. Eastern time (9:00 a.m. Pacific time) |
| Webcast: | Please click here to register. |
During the webinar, management expects to address the following topics:
- OneTest™ Franchise Program: Updates on preliminary interest from regional laboratories, the proposed royalty-based structure, and how the franchise model could expand distribution through partner-funded customer acquisition while the Company retains ownership of its technology and longitudinal biomarker data;
- 2027 Licensing Plans: The Company's plans to license its patented protein tumor marker approach to multi-cancer early detection (“MCED”) testing to clinical laboratories in the United States and internationally;
- Roll-Up Acquisition Strategy: Potential acquisitions of complementary businesses in health, wellness, early cancer detection, longevity testing, and nutrition, and how these businesses could benefit from access to the OneTest™ platform and shared public company infrastructure;
- FDA and Medicare Strategy: The Company's FDA planning for OneTest™ for Cancer, including management's perspective on the September 23, 2026 FDA advisory committee meeting concerning GRAIL's Galleri® MCED blood test, and its goal of achieving Medicare reimbursement for MCED by the end of 2028;
- Firefighter Cancer Screening: Potential Maryland legislation to expand the state's existing firefighter cancer screening grant program, under which 18 groups of Maryland fire departments were notified in March 2026 of awards totaling more than
$520,000 t o procure and administer OneTest™; and - A live question-and-answer session with management.
“Our goal is to expand the reach of OneTest by working with established laboratories, licensing our technology, and pursuing acquisitions that could bring additional customers onto our testing platform,” said Jonathan Cohen, President and Chief Executive Officer of 20/20 BioLabs. “On November 4, I look forward to discussing how these initiatives could support our growth in 2027, along with our FDA planning and the opportunities we see to expand state-funded firefighter cancer screening programs.”
The November 4 webinar is part of the Company's monthly investor webinar series, held on the first Wednesday of each month at 12:00 p.m. Eastern time. Investors and other interested parties are encouraged to submit questions in advance to AIDX@mzgroup.us. A replay will be made available through the Company's investor relations website following the event.
As part of its commitment to expanding access to early cancer detection, 20/20 BioLabs will provide webinar attendees with a promotional discount code for OneTest™ at the conclusion of the event. The offer will be available to all attendees, regardless of shareholder status.
Any potential franchise, licensing, or acquisition transaction would be subject to the negotiation and execution of definitive agreements and other customary conditions. There can be no assurance that any such transaction will be completed or generate revenue, or that the proposed Maryland legislation will be introduced or enacted. The Company's regulatory and reimbursement objectives are also subject to uncertainty.
Additional detail on the Company's business, results of operations, and risk factors is available in its filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The webinar will not include a discussion of the Company's third quarter 2026 financial results and is not expected to include the disclosure of any material non-public information.
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection blood test and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s tests are designed to be affordable and accessible and can be conveniently utilized at home using new, upper-arm capillary collection devices as an alternative to traditional venipuncture. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
For more information visit https://2020biolabs.com.
Forward-Looking Statements
Certain statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, regulatory strategy, reimbursement strategy, growth strategy, acquisition strategy, and financial needs. Forward-looking statements can be identified by words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,” “continue,” or the negative of these terms or other comparable expressions.
Forward-looking statements in this release include, but are not limited to, statements regarding the Company’s planned investor webinar and the topics management expects to address. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including the risks described in the Company’s filings with the U.S. Securities and Exchange Commission.
There can be no assurance that the Company will complete any strategic transaction on any particular timeline, or at all. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events, except as required by applicable law.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us
